Estudio de validación externa internacional de las Directrices de la Sociedad Europea de Cardiología de 2014 sobre la prevención de la muerte cardíaca súbita en la miocardiopatía hipertrófica (EVIDENCE-HCM)
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Ver abstracta en PubMed
Resumen
Este resumen es generado por máquina.El modelo HCM Risk-SCD identifica con precisión a los pacientes con cardiomiopatía hipertrófica con alto riesgo de muerte súbita cardíaca (SCD), lo que ayuda en las decisiones profilácticas sobre el desfibrilador implantable.
Área De La Ciencia
- Cardiología
- Estratificación del riesgo clínico
- Electrofisiología
Sus Antecedentes
- La identificación de pacientes con miocardiopatía hipertrófica (MHC) en riesgo de muerte súbita cardíaca (SCD) es crucial para la implantación profiláctica de un desfibrilador implantable (ICD, por sus siglas en inglés).
- Las directrices de la Sociedad Europea de Cardiología (ESC) de 2014 introdujeron el modelo HCM Risk-SCD para estimar el riesgo de ECS a 5 años.
Objetivo Del Estudio
- Para validar externamente la precisión del pronóstico del modelo de riesgo-SCD HCM de la ESC de 2014.
- Evaluar el rendimiento del modelo en una cohorte diversa de pacientes internacionales.
Principales Métodos
- Estudio de cohorte observacional, retrospectivo y longitudinal.
- Validación del modelo HCM Risk-SCD utilizando datos de 3703 pacientes en múltiples regiones geográficas.
- Análisis de la calibración, discriminación (índice C) y estadística D.
Principales Resultados
- El modelo HCM Risk-SCD demostró un buen rendimiento con una pendiente de calibración de 1,02 y un índice C de 0,70.
- En un análisis completo de casos, los pacientes con riesgo pronosticado de ECS a 5 años ≥6% tuvieron una incidencia observada del 8,9%.
- El modelo sugiere que por cada 13 implantaciones de DIC en pacientes de alto riesgo (≥6% de riesgo pronosticado), se podría salvar una vida por DIC.
Conclusiones
- El modelo HCM Risk-SCD proporciona información pronóstica precisa para los pacientes con miocardiopatía hipertrófica.
- El modelo puede guiar eficazmente la orientación de la terapia con desfibrilador cardioverter implantable a las personas con mayor riesgo de muerte súbita cardíaca.
Contact us Si estos videos no son relevantes.
Contact us Si estos videos no son relevantes.
Videos de Conceptos Relacionados
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...